PHARMACEUTICAL 2020

Abbott Laboratories
Rank 32 of 363



TOP RATED 2020

RealRate

PHARMACEUTICAL 2020

Abbott Laboratories
Rank 32 of 363

Abbott

The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abbott Laboratories compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 84% points.The greatest weakness of Abbott Laboratories is the variable Assets, Current, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 385%, being 147% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	15,667,000
Cost of Goods Sold	13,231,000
Intangible Assets	40,220,000
Liabilities, Current	10,863,000
Liabilities, Non-Current	0
Other Assets	3,962,000
Other Compr. Net Income	-879,000
Other Expenses	2,996,000
Other Liabilities	0
Other Net Income	215,000
Other Revenues	31,904,000
Property and Equipment	8,038,000
Research and Development	2,440,000
Selling, General and Administrative Expense	9,765,000

Output Variable	Value in 1000 USD
Assets	67,887,000
Liabilities	10,863,000
Expenses	28,432,000
Revenues	31,904,000
Stockholders Equity	57,024,000
Net Income	3,687,000
Comprehensive Net Income	3,247,500
BaseVar	70,090,000
ECR before LimitedLiability	324%
Economic Capital Ratio	385%